Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Choosing between equal and cap weight depends on goals and risk tolerance. This quick guide compares the two for retirement suitability.
24,329 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Icahn Enterprises just added a sizable stake in Centuri Holdings, signaling a continued conviction in North America's...
Pinterest faces headwinds after a price-target cut to $27. This story outlines three critical steps that could unlock...
Bitcoin and XRP lead the 2026 debate on how to deploy $1,000 in crypto, with macro momentum and policy shifts potenti...
When a company’s stock doubles and an insider sells a large block, investors should ask: what’s really going on? This...
XRP exchange-traded funds booked their first monthly net outflow after a $1.2 billion rally, signaling a shift in inv...
EQT Corp is becoming a cash machine, with free cash flow rising and margins expanding. Wall Street is warming to the ...
Workers say their benefits aren’t safety nets but leverage points used to keep them in place. This timely report expl...
Amazon launches a $200 billion AI-focused capex plan for 2026, with Trainium and Anthropic in the mix. Here’s what in...
A robot rollout tied to Melania Trump ignites a national debate over funding and the future of public schools. The te...
A once-sacrosanct pledge to never dump bitcoin treasury holdings is showing cracks as firms explore selling slices to...
A senior Rogers Corp. executive sold 830 shares for about $113,000, sparking questions about what it means for the st...